IL6 and diabetes mellitus: This study showed that 12 weeks of oral treatment of TRF in rats with STZ-induced diabetes reduces expression of the markers of retinal inflammation including IL-1β, IL-6, TNF-α, IFN-γ, MCP-1, and iNOS.